INTRODUCTIONThe move towards cellular risk markers
Why non-coding RNA?
Objectives
Approach
Take home message
About the author
CHAPTER I: BIOGENESIS AND MODES OF ACTION OF MIRS AND CIRCULAR AND LONG NON-CODING RNAS
1.1 MiRs 1.1.1 Biogenesis of miRs
1.1.2 MiR modes of action
1.1.3 Naming of miRs
1.1.4 Useful resources on miRs
1.2 Circular RNAs
1.2.1 Biogenesis of circular RNAs
1.2.2 Circular RNAs modes of action
1.2.3 Useful resources on circ-RNAs 1.3 LncRNAs
1.3.1 Biogenesis of lncRNAs
1.3.2 Modes of Action of lncRNAs
1.2.3 Useful resources on lncRNAs
CHAPTER II: OBESITY, INSULIN RESISTANCE IN ADIPOSE TISSUE AND THERMOGENESIS
2.1 Mechanisms in white adipogenesis
2.1.1 Role of non-coding RNA in white adipogenesis 2.2 Inflammation and insulin resistance in obese white adipose tissue
2.2.1 Role of non-coding RNA in inflammation and insulin resistance in obese white adipose tissue
2.3 Mechanisms in brown adipogenesis and thermogenesis
2.3.1 Role of non-coding RNA in brown adipogenesis and thermogenesis
2.4 Mechanisms in browning of white adipose tissues
2.4.1 Role of non-coding RNAs in browning of white adipose tissue
CHAPTER III: TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE
3.1 Mechanisms in β cell maturation
3.1.1 Non-coding RNA related to β cell maturation
3.2 Mechanisms in insulin signaling in the pancreas
3.2.1 Non-coding RNAs in insulin signaling in type 2 diabetes 3.3 Inflammation in the pancreas, insulin resistance, and type 2 diabetes
3.3.1 Non-coding RNA related to inflammation in the pancreas, with insulin resistance and type 2 diabetes
3.4 Non-alcoholic fatty liver disease with obesity and type 2 diabetes
3.4.1 Non-coding RNA related to non-alcoholic fatty liver disease
CHAPTER IV: ATHEROSCLEROSIS
4.1 Endothelial injury, inflammation, and apoptosis
4.1.1 Non-coding RNAs in endothelial injury, inflammation, and apoptosis
4.2 Fibroproliferative remodeling and plaque destabilization
4.2.1 Non-coding RNA in fibroproliferative remodeling and plaque destabilization
CHAPTER V: CARDIOMYOPATHY AND HEART FAILURE
5.1 Mechanisms in cardiomyopathy and heart failure
5.2 Non-coding RNAs in cardiomyopathy and heart failure 5.2.1 Non-coding RNAs in cardiac hypertrophy
5.2.2 Non-coding RNAs in cardiac fibrosis and ECM deposition
5.2.3 Non-coding RNAs in cardiac inflammation
5.2.4 Non-coding RNAs in cardiac angiogenesis
5.2.5 Non-coding RNAs in cardiac apoptosis
5.3 Metabolic syndrome: the link between metabolic and cardiovascular diseases.
5.3.1 Definition of metabolic syndrome
5.3.2 Oxidative stress and metabolic syndrome
5.3.3 Metabolic syndrome and cardiovascular risk
5.3.4 Non-coding RNAs and metabolic syndrome components
CHAPTER VI: CANCER
6.1 Mechanisms of cancer progression
6.1.1 Induction of stemness
6.1.2 Induction of EMT
6.1.3 Induction of insulin sensitized state, cancer cell proliferation, and protection against apoptosis
6.1.4 Induction of glycolysis and repression of OXPHOS
6.1.5 Induction of angiogenesis
6.1.6 Repression of anti-tumor immunity
6.1.7 EGFR signaling and cancer progression
6.1.8 BMI1 and EZH2 in cancer progression
6.2 Non-coding RNAs related to metabolic and cardiovascular diseases are also involved in cancer progression
6.2.1 Non-coding RNAs and stemness
6.2.1 Non-coding RNAs and EMT
6.2.3 Non-coding RNAs and insulin sensitized state, cancer
